We also found that most of the immune checkpoints currently used in therapy (e.g., PDCD1, CTLA4) were positively correlated with the expression of NUDT21, implying that it may be possible that PAAD may benefit more from immune-associated therapies against these checkpoints. Here, NUDT21 is linked to pancreatic adenocarcinoma.